Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014045 | 1.00 | ABHD6 (0.63) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29640836 | 0.92 | ABHD6 (0.54) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15616589 | 0.92 | ABHD6 (0.54) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL18109844 | 0.91 | ABHD6 (0.53) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29507117 | 0.89 | CHRM4 (0.51) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL595638 | 0.89 | CHRM4 (0.51) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8200750 | 0.84 | NOTUM (0.64) | ABHD6GPR119MEN1KMT2ANPSR1 | |
| SCHEMBL3899182 | 0.84 | ESR2 (0.61) | ABHD6GPR119DHODHNOTUMESR2 | |
| SCHEMBL18921803 | 0.84 | ABHD6 (0.64) | ABHD6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1058537 | 0.83 | NR1H2 (0.62) | ABHD6GPR119DHODHNOTUMESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110724047-B | Method for preparing aromatic carboxylic acid compound | 中国科学院大连化学物理研究所 | 2020-10-30 | — | — | CN | claimed |
| CN-110724047-A | Method for preparing aromatic carboxylic acid compound | 中国科学院大连化学物理研究所 | 2020-01-24 | — | — | CN | claimed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025217330-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2001012600-A9 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| CN-1323295-A | Azabicyclic compounds for modulating cell adhesion inhibition | AVENTIES PHARMACEUTICAL LTD (GB) | 2001-11-21 | — | — | CN | disclosed |
| WO-2001064640-A1 | 2,3-DIHYDRO-1H-INDOLINYL-ALKANOIC ACIDS AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
| EP-1114028-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | Aventis Pharma Limited (GB) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001012600-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000015612-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | ABHD6 3309/4885TUBB4A 1557/4885TUBB 1074/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | ABHD6 1043/4885TUBB4A 2787/4885TUBB 2858/4885 |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | ABHD6 621/4885TUBB4A 3099/4885TUBB 3188/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | ABHD6 2005/4885TUBB4A 1654/4885TUBB 1635/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | ABHD6 4161/4885TUBB4A 337/4885TUBB 146/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | ABHD6 3912/4885TUBB4A 689/4885TUBB 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.